Evaluation of clinical and laboratory characteristics and factors affecting mortality in 500 hospitalized COVID-19 patients A retrospective study

被引:3
作者
Konya, Petek S. [1 ]
Demirturk, Nese [1 ]
Korkmaz, Derya [1 ]
Tunay, Havva [1 ]
Kosar, Elif Betul [1 ]
机构
[1] Afyonkarahisar Hlth Sci Univ, Dept Infect Dis & Clin Microbiol, Afyon, Turkey
关键词
COVID-19; mortality; favipiravir; FAVIPIRAVIR; WUHAN;
D O I
10.15537/smj.2022.43.11.20220641
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To evaluate the clinical and laboratory characteristics of COVID-19 patients admitted to Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey, and to determine the factors affecting mortality. Methods: A total of 500 patients who were diagnosed with COVID-19 between 19th of March and 30th of September 2020 in Afyonkarahisar Health Sciences University, Faculty of Medicine, Pandemic Service, Afyonkarahisar, Turkey, were retrospectively investigated for this study. These individuals' prognoses, demographic, clinical, laboratory, and radiological information were examined and recorded retrospectively. Comparisons were carried out between the characteristics of patients with a prognosis of death and those who recovered. Results: Of the 500 definite COVID-19 cases included in the study, 53.8% were male and the mean age was 57.6 +/- 15.1 (18-88 years). The most common comorbidities were hypertension and diabetes mellitus. A total of 45 (9%) patients developed mortality. Factors such as advanced age, male gender, shortness of breath, fever at admission, comorbid conditions such as hypertension, diabetes mellitus, cardiovascular diseases, lymphopenia, high C-reactive protein, high D-dimer, and high ferritin in the laboratory were found to be important risk factors for mortality. Treatments such as hydroxychloroquine, favipiravir, and lopinavir/ritonavir were not found to have lower mortality rates than one another. Conclusion: Considering these elements when assessing patients and adjusting the course of treatment according to the recommendations of the most recent guidelines may lower mortality.
引用
收藏
页码:1254 / 1259
页数:6
相关论文
共 24 条
[1]   Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States [J].
Aggarwal, Saurabh ;
Garcia-Telles, Nelson ;
Aggarwal, Gaurav ;
Lavie, Carl ;
Lippi, Giuseppe ;
Henry, Brandon Michael .
DIAGNOSIS, 2020, 7 (02) :91-96
[2]   Hydroxychloroquine: From Malaria to Autoimmunity [J].
Ben-Zvi, Ilan ;
Kivity, Shaye ;
Langevitz, Pnina ;
Shoenfeld, Yehuda .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2012, 42 (02) :145-153
[3]  
Bhimraj A, IDSA guidelines on the treatment and management of patients with COVID-19
[4]  
Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
[5]   Radiological findings of COVID-19 pneumonia [J].
Ceylan, Naim ;
Savas, Recep .
EURASIAN JOURNAL OF PULMONOLOGY, 2020, 22 (04) :19-24
[6]   Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial [J].
Chen, Chang ;
Zhang, Yi ;
Huang, Jianying ;
Yin, Ping ;
Cheng, Zhenshun ;
Wu, Jianyuan ;
Chen, Song ;
Zhang, Yongxi ;
Chen, Bo ;
Lu, Mengxin ;
Luo, Yongwen ;
Ju, Lingao ;
Zhang, Jingyi ;
Wang, Xinghuan .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[7]   Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients [J].
Dessie, Zelalem G. ;
Zewotir, Temesgen .
BMC INFECTIOUS DISEASES, 2021, 21 (01)
[8]   A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 [J].
Doi, Yohei ;
Hibino, Masaya ;
Hase, Ryota ;
Yamamoto, Michiko ;
Kasamatsu, Yu ;
Hirose, Masahiro ;
Mutoh, Yoshikazu ;
Homma, Yoshito ;
Terada, Masaki ;
Ogawa, Taku ;
Kashizaki, Fumihiro ;
Yokoyama, Toshihiko ;
Koba, Hayato ;
Kasahara, Hideki ;
Yokota, Kazuhisa ;
Kato, Hideaki ;
Yoshida, Junichi ;
Kita, Toshiyuki ;
Kato, Yasuyuki ;
Kamio, Tadashi ;
Kodama, Nobuhiro ;
Uchida, Yujiro ;
Ikeda, Nobuhiro ;
Shinoda, Masahiro ;
Nakagawa, Atsushi ;
Nakatsumi, Hiroki ;
Horiguchi, Tomoya ;
Iwata, Mitsunaga ;
Matsuyama, Akifumi ;
Banno, Sumi ;
Koseki, Takenao ;
Teramachi, Mayumi ;
Miyata, Masami ;
Tajima, Shigeru ;
Maeki, Takahiro ;
Nakayama, Eri ;
Taniguchi, Satoshi ;
Lim, Chang Kweng ;
Saijo, Masayuki ;
Imai, Takumi ;
Yoshida, Hisako ;
Kabata, Daijiro ;
Shintani, Ayumi ;
Yuzawa, Yukio ;
Kondo, Masashi .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)
[9]   Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019 [J].
Fan, Jianghong ;
Zhang, Xinyuan ;
Liu, Jiang ;
Yang, Yuching ;
Zheng, Nan ;
Liu, Qi ;
Bergman, Kimberly ;
Reynolds, Kellie ;
Huang, Shiew-Mei ;
Zhu, Hao ;
Wang, Yaning .
CLINICAL INFECTIOUS DISEASES, 2020, 71 (12) :3232-3236
[10]   Favipiravir (T-705), a novel viral RNA polymerase inhibitor [J].
Furuta, Yousuke ;
Gowen, Brian B. ;
Takahashi, Kazumi ;
Shiraki, Kimiyasu ;
Smee, Donald F. ;
Barnard, Dale L. .
ANTIVIRAL RESEARCH, 2013, 100 (02) :446-454